Startup Rise America News’ Post

TechBio startups are making drug development faster, cheaper and more effective. 💊 According to our exclusive new report in partnership with Dealroom.co, European TechBio companies raised $1.2 billion in VC funding in 2023. The report maps 450+ TechBio startups working to change drug discovery at every phase — from research, to clinical trials and market access. We answer these questions and much more - Who are the most active TechBio investors? Which sectors attract the most funding? Where are the TechBio hubs? Download the full report on our blog and dive in to key takeaways from Estelle Botbol and Daria Gherghelas of our Health & TechBio team 👇 https://lnkd.in/ews4rrB8 #techbio #drugdiscovery #healthtech #biotech Orakl Oncology, Molecule AG, Flinn.ai, Seqera, IOMED, Daria Gherghelas, Andrea Zitna, Hendrik Steenfadt, MD

📣 Exciting Announcement! We’re excited to announce that Inside Therapeutics has secured a €1.3M seed investment!     This funding strengthens our mission to accelerate patient access to RNA therapeutics thanks to our innovative nanomedicine formulation systems.    Who are we?  Founded by Thomas Guerinier, Audrey Nsamela, Alexis PEYROLES, Matthieu KERHUEL and Robin Oliveres, Inside Therapeutics aims to simplify access to nanoparticle formulation and streamline the nanoparticle manufacturing scale-up process to accelerate the development of nanomedicine and RNA therapies. This investment positions Inside Tx as a major actor in the nanomedicine manufacturing field.    Our next steps:  - Boost sales of our first product, Tamara  - Industrialize our proprietary NanoP technology  - Accelerate our global expansion, with a focus on the USA  - Recruit top talent and build a strong, efficient team    A huge thank you to Newfund, SKALEPARK, Marc Le Bozec, and our amazing team for making this happen! Stay tuned for more exciting updates and join us in reshaping the RNA and nanomedicine field! To learn more, check our press release: https://lnkd.in/eitrKmk7 #biotech #RNAtherapies #LNP #Fundraise #startup

Guess who has been featured in Speedinvest and Dealroom.co's new 'TechBio x Drug Discovery' report? If you guessed Automata, you'd be correct! Follow the link in the post below to download the full version and see who we're listed alongside 🔽

Very pleased to see our very own Turbine mentioned a couple times in the excellent #TechBio + #DrugDiscovery report by Speedinvest & Dealroom.co. Well worth a read if you want to geek out over the +450 European Tech Bio startups making drug development more efficient. 💊 🤓 We're continuing to invest in this exciting area. Hopefully next edition we'll get Mercia Ventures on that list of top 18 European investors in this space... 🤔 #startups #drugdevelopment #lifesciences #healthcare #venturecapital

💸 IPOs are back with nearly $700M raised in a single day! Recent biotech IPOs from Bicara, Zenas, and MBX Biosciences collectively raised nearly $700M, signalling renewed investor confidence. Bicara raised $108M to advance immuno-oncology therapies, while Zenas secured $198M for autoimmune treatments. MBX Biosciences, developing hormone-based therapies, raised $236M. As 2024 shows increasing interest in the public markets, biotech companies are taking advantage of the window. However, experts remain cautious about the sustainability of this surge amidst regulatory challenges and market fluctuations. Prior to Thursday, the last time three biotechs went public in the same week was in early February, when cell therapy developer Kyverna Therapeutics, gene editing company Metagenomi and anti-aging startup Telomir Pharmaceuticals raised about $420 million over two days. There is a backlog of startups that are relying on later funding rounds to stay afloat and wait for the right opportunity. Their arrival onto the market may be delayed by U.S. elections in November and uncertainty around interest rates, however. “We don’t anticipate a rapid recovery until the dust settles on macro uncertainties, but expect to see an uptick in companies going public in early ’25,” wrote Jefferies analyst Michael Yee in an investor note this summer. #Biotech #IPO #HealthcareInnovation #Investment #Biopharma

NEW: Terray Therapeutics becomes the latest AI-focused biotech startup to raise a megaround, just closing a $120 million Series B round. Founding CEO Jacob Berlin, PhD told me his Los Angeles-area biotech aims to enter the clinic in 2026 with its first drug candidate. In the meantime, they will keep scaling a massive dataset of protein-ligand binding interactions. Today that data is 50x larger than what's publicly available, he said, and he believes this is the "key dataset missing for AI-driven drug discovery." “Every single molecule we bring forward has a scaffold that has been de novo discovered and optimized at Terray from the ground up,” Berlin told me. “That’s totally different than what you see across the ecosystem, where AI models have to stay close to historical sets of data because they don’t have our hardware innovation.” My latest exclusive for Endpoints News, including some details on how they developed a partial latent diffusion model to generate new small molecules:

#fundingalert 💼Company: Neurenati Therapeutics  💰Funding: $1.2Million ⚡Round: Seed 👥Investors: Genson Capital Neurenati Therapeutics was founded by Nicolas Pilon, Rodolphe Soret.  The funding will be used by the company to expedite the development of NEU-001. A cutting-edge #biotechnology startup called Neurenati Therapeutics is creating a novel therapy for Hirschsprung’s illness. The company is dedicated to getting this treatment into clinical practice and has the backing of multiple #medical professionals, including #gastroenterologists and experts in clinical trials on rare disorders. Maxime Ranger Zhizi Zhao Benoit Dore Alexandre LeBeaut François Boutin, CPA Read more - https://lnkd.in/grySxF9a To share your startup story write us on - contact@startuprise.io #neurenatitherapeutics #biotechnology #meditech #news #healthtech #funding #startup

#News: Xaira Therapeutics, described as an integrated biotechnology company, launched Tuesday with $1 billion in an effort to transform #drugdiscovery and #drugdevelopment using #artificialintelligence. The San Francisco-based startup has brought together big names in AI research, drug development and venture capital to build and use an R&D platform. ARCH Venture Partners and Foresite Labs jointly incubated the #biotech and contributed funding. The funding from ARCH, which lists Alnylam Pharmaceuticals and Illumina among its successes, is the largest initial commitment in the almost 40-year history of the fund.  Robert Nelsen, managing director and co-founder of ARCH, explained the thinking behind the big bet. “We have reached the point where AI finally allows us to see biology in new ways, and translate those discoveries to better treatments for disease,” Read more from BioSpace 👇🏼 https://lnkd.in/dktfbJGv

Check out our latest publication in "Progress in Retinal and Eye Research." Titled "Investing in vision: Innovation in retinal therapeutics and the influence on venture capital investment," the article is authored by Partner Dr. Dmitrij Hristodorov, Senior Associate Tim Lohoff, Ph.D., General Partner Nanna Lüneborg, Managing Partner Geert-Jan Mulder, and Advisor Simon J. Clark. The article provides a comprehensive review of the past two decades, covering achievements, challenges, and contextualizing investments, partnerships, and acquisitions. It concludes with an optimistic outlook and potential roadmap for novel retinal therapeutics, emphasizing the potential to stimulate further venture capital investments for the development and delivery of new therapies to patients in need. Access the full article by clicking the link below on our website. #RetinalTherapeutics #MedicalAdvancements #InnovationInHealthcare #VentureCapital #EyeHealth #Research #Publication #lifesciences #biotech

Ready for a mid-week 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐁𝐮𝐥𝐥𝐞𝐭𝐢𝐧? 🌟 Cash galore this week as biotechs raise significant rounds, from Series A to Series E! 📈 🍄 Elion Therapeutics raises an $81 Million Series B from Deerfield Management, AMR Action Fund, and Illinois Ventures to advance clinical-stage candidate SF001, a next-gen polyene antifungal currently being studied in a multiple-ascending dose study - congrats Kieren Marr! 💉 Kudos to Prakash Raman at InduPro for the $85 Millon Series A, together from The Column Group, Vida Ventures, MRL Ventures Fund LLC, Emerson Collective, and EUCLIDEAN CAPITAL, LLC, advancing a first candidate into the clinic and and early-stage pipeline of bispecific antibodies and antibody drug conjugates that use protein proximity to identify novel tumor selective target pairings 🧠 Alzheon, Inc. | Preserving Future Memories raises a $100 Million Series E led by Alerce Medical Technology Partners to advance the company's investigational therapies and diagnostic assays for patients with Alzheimer’s disease and other neurodegenerative disorders ⛰️ Bright Peak Therapeutics raises a $90 Million Series C led by Johnson & Johnson Innovation JJDC Inc, and new investors Venrock, KB Investment, and Northleaf Capital Partners Follow us at Biotech Leaders for more industry updates! #biotech #investment #deals #capital